# Philippe Aftimos

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/philippe-aftimos/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,166 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 36 |
| i10-index | 108 |
| Last Known Institution | Université Libre de Bruxelles |
| OpenAlex ID | https://openalex.org/A5078388793 |
| ORCID iD | 0000-0001-9946-4726 |
| Works | 329 |

## Researcher papers

- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial](https://scholariq.org/papers/elacestrant-oral-selective-estrogen-receptor-degrader-versus-standard-endocrine/)
- [Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study](https://scholariq.org/papers/trastuzumab-duocarmazine-in-locally-advanced-and-metastatic-solid-tumours-and/)
- [Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis](https://scholariq.org/papers/unravelling-triple-negative-breast-cancer-molecular-heterogeneity-using-an/)
- [Delivering precision oncology to patients with cancer](https://scholariq.org/papers/delivering-precision-oncology-to-patients-with-cancer/)
- [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://scholariq.org/papers/biomarker-analyses-in-the-phase-iii-ascent-study-of-sacituzumab-govitecan-versus/)
- [HER2-Low Breast Cancer: Molecular Characteristics and Prognosis](https://scholariq.org/papers/her2-low-breast-cancer-molecular-characteristics-and-prognosis/)
- [Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors](https://scholariq.org/papers/phase-ib-trial-with-birabresib-a-small-molecule-inhibitor-of-bromodomain-and/)
- [Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative](https://scholariq.org/papers/genomic-and-transcriptomic-analyses-of-breast-cancer-primaries-and-matched/)
- [Effect of the COVID-19 pandemic on cancer treatment and research](https://scholariq.org/papers/effect-of-the-covid-19-pandemic-on-cancer-treatment-and-research/)
- [Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial](https://scholariq.org/papers/patient-reported-outcomes-and-qualitative-interviews-in-patients-with-estrogen/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Medical Imaging Techniques and Applications](https://scholariq.org/topics/medical-imaging-techniques-and-applications/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Université Libre de Bruxelles](https://scholariq.org/institutions/universite-libre-de-bruxelles/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.